Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.66 |
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.57 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177850 | 0.89 | TLR8 (0.59) | TLR8TLR7NUDT1 | |
| SCHEMBL2743984 | 0.87 | TLR7 (0.72) | TLR8TLR7NUDT1 | |
| SCHEMBL6719001 | 0.85 | TLR7 (0.76) | TLR8TLR7 | |
| SCHEMBL8122384 | 0.85 | TLR7 (0.67) | TLR8TLR7NUDT1 | |
| SCHEMBL6104415 | 0.85 | TLR8 (0.63) | TLR8TLR7NUDT1 | |
| SCHEMBL12149588 | 0.85 | TLR7 (0.53) | TLR8TLR7NUDT1 | |
| SCHEMBL6723566 | 0.84 | TLR7 (0.65) | TLR8TLR7NUDT1 | |
| SCHEMBL23607269 | 0.84 | TLR8 (0.54) | TLR8TLR7NUDT1 | |
| SCHEMBL5452843 | 0.84 | TLR8 (0.57) | TLR8TLR7NUDT1 | |
| SCHEMBL6730371 | 0.84 | TLR8 (0.74) | TLR8TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122231-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-24 | — | — | US | claimed |
| US-20030212270-A1 | Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | claimed |
| US-20030119861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-06-26 | — | — | US | claimed |
| US-20020115861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-22 | — | — | US | claimed |
| EP-0582581-B1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING & MFG (US) | 1999-05-06 | — | — | EP | claimed |
| US-5389640-A | Viricides, antitumor agents | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-14 | — | — | US | claimed |
| EP-0582581-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO 4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-02-16 | — | — | EP | claimed |
| WO-1992015582-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-09-17 | — | — | WO | claimed |
| EP-3568162-B1 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | NEKTAR THERAPEUTICS (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12214045-B2 | Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods | NEKTAR THERAPEUTICS (US) | 2025-02-04 | — | — | US | disclosed |
| US-12054553-B2 | Immunotherapeutic tumor treatment method | NEKTAR THERAPEUTICS (US) | 2024-08-06 | — | — | US | disclosed |
| CN-110582300-B | Tumor immunotherapeutic treatment method | 尼克塔治疗公司 | 2024-08-02 | — | — | CN | disclosed |
| US-12030940-B2 | Immunotherapeutic tumor treatment method | NEKTAR THERAPEUTICS (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230372500-A1 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | NEKTAR THERAPEUTICS (US) | 2023-11-23 | — | — | US | disclosed |
| EP-0582581-B1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING & MFG (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0872478-A2 | Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5741909-A | PHARMACEUTICAL COMPOSITIONS WHICH ACT AS ANTIVIRAL AGENTS, INDUCE BIOSYNTHESIS OF INTERFERON AND INHIBIT TUMOR FORMATION IN ANIMALS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| US-5605899-A | VIRICIDES, BIOSYNTHESIS OF INTERFERONS, ANTITUMOR AGENTS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5389640-A | Viricides, antitumor agents | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| WO-1992015582-A1 | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372500-A1 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | TLR7, TLR8, TLR3 | TLR8 2/4885TLR7 1/4885NUDT1 1567/4885 |
| US-20030212270-A1 | Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines | IFNAR1, IRF3, IFNG | TLR8 382/4885TLR7 101/4885NUDT1 58/4885 |
| US-12214045-B2 | Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods | TLR7, TLR8, TLR3 | TLR8 2/4885TLR7 1/4885NUDT1 2266/4885 |
| US-12054553-B2 | Immunotherapeutic tumor treatment method | IL2RA, IL2, TLR3 | TLR8 15/4885TLR7 6/4885NUDT1 3163/4885 |
| US-20020115861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines | IFNAR1, IFNG, IRF3 | TLR8 335/4885TLR7 54/4885NUDT1 47/4885 |
| US-20040122231-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | UGT1A4, QARS1, HTR4 | TLR8 1825/4885TLR7 1287/4885NUDT1 118/4885 |
| US-20030119861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | IRF3, IFNAR1, IFNG | TLR8 336/4885TLR7 105/4885NUDT1 61/4885 |
| US-12030940-B2 | Immunotherapeutic tumor treatment method | CD274, TLR7, PDCD1LG2 | TLR8 5/4885TLR7 2/4885NUDT1 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.